Features | Partner Sites | Information | LinkXpress
Sign In

Sensitive Test Enables Early Diagnosis of Rheumatoid Arthritis

By Labmedica International staff writers
Posted on 14 Dec 2011
A highly sensitive and specific laboratory test enables the early diagnosis of rheumatoid arthritis (RA), which in turn allows for successful treatment of this autoimmune disease.

The new Anti-CCP hs (high sensitive) test is the most recent development in the area of anticitrullinated peptide antibody (ACPA) testing. This innovative enzyme immunoassay combines the advantages of mutated citrullinated vimentin (MCV) antibody detection (anti-MCV), with the power of modern peptide synthesis. It an effective tool for the rapid and precise routine diagnosis of suspected RA and the diagnosis of early rheumatoid arthritis.

In combination with medical history, clinical observations, and imaging techniques, serological tests like Anti-CCP hs are the basis for early diagnosis of RA. Early diagnosis is critical to patient outcomes because early, effective treatment can avert damage to the joints and maintain their function.

Orgentec Diagnostika (Mainz, Germany) developed the Anti-CCP hs test; it also develops and markets test systems for autoimmune diagnostics and serological tests for infectious disease. Orgentec has developed numerous highly specific ELISA test systems, immunoblot and immunofluorescence tests, the Alegria random access analyzer, and the rheumachec rapid test.

Related Links:
Orgentec Diagnostika

Dubai Bio Expo-2015



view channel

Biomarkers Identify Pregnant Women with Lupus or APL at Risk for Adverse Outcomes

A consortium of researchers has found that testing blood of pregnant women with systemic lupus erythematosus (SLE) or antiphospholipid antibodies (APL) for certain biomarkers can identify and stratify low- vs. high-risk patients early in pregnancy. "Given that over 20% of pregnant women with lupus APL experience adverse... Read more

Industry News

view channel

Diagnostic Company Acquisition to Ease Market Entry and Shorten Development Time for New Tests

Two North American manufacturers of rapid diagnostic tests are combining in order to pool their products for rapid entry into the diagnostic product market and to boost development of new tests. NOWDiagnostics Inc. (Springdale, AR, USA) recently completed the acquisition of ZBx Corporation (Toronto, Canada).... Read more
Copyright © 2000-2015 Globetech Media. All rights reserved.